Farmak International at CPHI 2025: Advancing Sterile Injectables Globally

Farmak International marked a strong presence at CPHI Worldwide 2025, the leading global pharmaceutical exhibition that brought together over 62,000 attendees and 2,400 exhibitors from more than 160 countries.

This year’s exhibition highlighted Farmak International’s expanding role in the global pharmaceutical market, with particular attention drawn to its sterile injectables portfolio and focus therapeutic areas — iron therapies, metabolic and endocrine disorders, psychiatry, oncology and immunology, and anaesthesiology & intensive care.

Strong Interest in Farmak International’s Therapeutic Portfolio

Visitors and business partners showed high interest in Farmak International’s complex generics and sterile injectable range, particularly across the starred therapeutic areas showcased at the event. The level of engagement reaffirmed company’s growing reputation as a trusted partner for high-quality, EU GMP–certified manufacturing and global supply in critical-care and hospital settings.

Celebrating 100 Years of Innovation

Alongside business meetings, this year’s CPHI also became a platform to share Farmak’s 100-year story, a story of manufacturing excellence, innovation, and sustainable growth. The booth featured a commemorative logo, photo zone, and exhibition materials dedicated to the company’s century-long heritage, which drew strong reactions from visitors who were often surprised and inspired by Farmak brand’s long history and international evolution.

Presenting the New Sterile Injectables Plant in Spain

A central focus of Farmak International’s presentation was its state-of-the-art sterile injectables plant near Barcelona, Spain, purpose-built for complex and long-acting formulations. Together with EU GMP-certified facilities in Ukraine, this site strengthens Farmak Group’s integrated production model, ensuring flexibility, reliability, and high-quality standards across markets.

CEO Statement

Reaching 100 years as a company is a proud milestone, but what truly defines Farmak today is how we turn that legacy into innovation and global partnerships. The strong attention our portfolio received at CPHI 2025 shows that our capabilities in sterile injectables are recognized worldwide, and that our investments in complex generics are delivering real impact. We will continue expanding our reach and contributing to healthcare systems with reliable, high-quality medicines

Viktor Kostiuk CEO of Farmak International

Adding to the company’s achievements, Farmak International was recognized as a finalist at the CPHI Pharma Awards 2025 in the At the Heart of Pharma category, an impressive accomplishment at its very first participation.

Looking Ahead

Farmak International’s participation at CPHI 2025 underscored its commitment to global growth, product excellence, and dependable partnerships. With an expanding network of commercial offices and manufacturing capabilities, the company continues to build on its heritage while focusing on the next generation of complex and sterile injectable medicines.

📄 Download our product portfolio to explore Farmak International’s therapeutic focus areas and partnership opportunities.